Bogang Wu

12PUBLICATIONS
53CO-AUTHORS
Tumour immunologyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Apr 03, 2026
TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer.

Bogang Wu, Win Thant, Elena Bitman

|Jan 02, 2025
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.

Rachel O Abelman, Bogang Wu, Haley Barnes

|Dec 16, 2024
A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast Cancer.

Bogang Wu, Win Thant, Elena Bitman

|May 06, 2024
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer.

Aditya Bardia, Sheng Sun, Nayana Thimmiah

|Feb 25, 2023
Mechanisms of Resistance to Antibody-Drug Conjugates.

Rachel Occhiogrosso Abelman, Bogang Wu, Laura M Spring

|Feb 02, 2023
BRCA1 deficiency in mature CD8+ T lymphocytes impairs antitumor immunity.

Bogang Wu, Leilei Qi, Huai-Chin Chiang

Pageof 2

Frequent Collaborators

3 joint publications

Tyler J Curiel

3 joint publications

Leif W Ellisen

3 joint publications

Rachel Occhiogrosso Abelman

2 joint publications

Aditya Bardia